Do metallothioneins affect the response to treatment in testis cancers?

Eid, Hanna; Gergely, Lajos; Bodrogi, I.; Institoris, Etel; Bak, M.

doi:10.1007/s004320050130

Cited by 14 publications

(13 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, however, MT-protein expression certainly did not differ between primary germ-cell tumours of responding and of non-responding patients. Data on MT-protein expression in patients with disseminated non-seminoma in the mentioned studies (15, 31 and 14 patients in studies by Chin et al (1993) and Eid et al (1998) and in the present study respectively) are, as far as evaluable, still comparable. Overall, MT-protein over-expression is found in at least 85% of the tumours of responding patients.…”

Section: Resultssupporting

confidence: 52%

“…In our study, no direct relation was observed between protein levels of MT and total p53. In ductal carcinoma in situ of the breast, MT and p53 expression, though both elevated, were not found to be correlated (Douglas-Jones et al, 1997), while Eid et al (1997Eid et al ( , 1998 reported that MT and p53 expression in germ-cell tumours was related. The functional significance of MT as distributor of essential co-factors (zinc/copper) clearly merits further study.…”

Section: Resultsmentioning

confidence: 93%

“…The more advanced-stage non-seminomas tended to stain more heavily for MT. Moreover, Eid et al (1998) have reported a correlation between MT levels of human primary germ-cell testicular tumours and response to chemotherapy. In our study, however, MT-protein expression certainly did not differ between primary germ-cell tumours of responding and of non-responding patients.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Role of metallothionein in cisplatin sensitivity of germ-cell tumours

Meijer

Timmer²,

Vries

et al. 2000

Int. J. Cancer

View full text Add to dashboard Cite

Section: Resultssupporting

confidence: 52%

Section: Resultsmentioning

confidence: 93%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Role of metallothionein in cisplatin sensitivity of germ-cell tumours

Meijer

Timmer²,

Vries

et al. 2000

Int. J. Cancer

View full text Add to dashboard Cite

“…Using the meta-analysis, no association of MT staining and tumor stage was observed in bladder [44], [83], [107], endometrial [108], [109], testicular [6], [98], kidney [110], [111], and head and neck cancer [41], [51]. There are also studies regarding tumors of breast [45], liver [74], and stomach [43] showing no significant association between MT staining and the tumor stage (Table 2).…”

Section: Resultsmentioning

confidence: 97%

Metallothionein – Immunohistochemical Cancer Biomarker: A Meta-Analysis

et al. 2014

View full text Add to dashboard Cite

Metallothionein (MT) has been extensively investigated as a molecular marker of various types of cancer. In spite of the fact that numerous reviews have been published in this field, no meta-analytical approach has been performed. Therefore, results of to-date immunohistochemistry-based studies were summarized using meta-analysis in this review.Web of science, PubMed, Embase and CENTRAL databases were searched (up to April 30, 2013) and the eligibility of individual studies and heterogeneity among the studies was assessed. Random and fixed effects model meta-analysis was employed depending on the heterogeneity, and publication bias was evaluated using funnel plots and Egger's tests.A total of 77 studies were included with 8,015 tissue samples (4,631 cases and 3,384 controls). A significantly positive association between MT staining and tumors (vs. healthy tissues) was observed in head and neck (odds ratio, OR 9.95; 95% CI 5.82–17.03) and ovarian tumors (OR 7.83; 1.09–56.29), and a negative association was ascertained in liver tumors (OR 0.10; 0.03–0.30). No significant associations were identified in breast, colorectal, prostate, thyroid, stomach, bladder, kidney, gallbladder, and uterine cancers and in melanoma. While no associations were identified between MT and tumor staging, a positive association was identified with the tumor grade (OR 1.58; 1.08–2.30). In particular, strong associations were observed in breast, ovarian, uterine and prostate cancers. Borderline significant association of metastatic status and MT staining were determined (OR 1.59; 1.03–2.46), particularly in esophageal cancer. Additionally, a significant association between the patient prognosis and MT staining was also demonstrated (hazard ratio 2.04; 1.47–2.81). However, a high degree of inconsistence was observed in several tumor types, including colorectal, kidney and prostate cancer.Despite the ambiguity in some tumor types, conclusive results are provided in the tumors of head and neck, ovary and liver and in relation to the tumor grade and patient survival.

show abstract

“…In a variety of human germ tumour cell lines, the increased MT expression observed was concomitant with increased cisplatin resistance 135,136 . In contrast, in patients with germ cell testicular tumours, high MT immunoreactivity was found to predict a better response rate to chemotherapy, opposing the hypothesis that MT overexpression contributes to cisplatin resistance in this tumour type 137 . Additionally, it is known that metastatic testicular germ cell tumours are cured in most cases using cisplatin‐based combination chemotherapy 138 .…”

Section: Testicular Neoplasiamentioning

confidence: 99%

Metallothionein expression in human neoplasia

et al. 2004

View full text Add to dashboard Cite

The metallothionein family is a class of low-molecular-weight, cysteine-rich proteins with high affinity for metal ions. Four major isoforms (metallothionein-1, -2, -3, and -4) have been identified in mammals, involved in many pathophysiological processes, including metal ion homeostasis and detoxification, protection against oxidative damage, cell proliferation and apoptosis, drug and radiotherapy resistance and several aspects of the carcinogenic process. In the present review we examine the expression of metallothionein in different human tumours and its correlation with histopathological variables, tumour cell proliferation or apoptosis, resistance to radiation or chemotherapy, patient survival and prognosis. A variable profile of metallothionein and its isoforms' expression has been observed in different cancer types. Although metallothionein expression has been implicated in carcinogenic evolution, its use as a marker of tumour differentiation, cell proliferation and prognosis predictor remains unclear. Detailed studies focused on the expression of metallothionein isoforms and isotypes in different tumour types could elucidate the role of this group of proteins in the carcinogenic process, delineating its possible clinical significance for the management of patients.

show abstract

Do metallothioneins affect the response to treatment in testis cancers?

Cited by 14 publications

References 22 publications

Role of metallothionein in cisplatin sensitivity of germ-cell tumours

Role of metallothionein in cisplatin sensitivity of germ-cell tumours

Metallothionein – Immunohistochemical Cancer Biomarker: A Meta-Analysis

Metallothionein expression in human neoplasia

Contact Info

Product

Resources

About